ArticleAmerican heart journal plus : cardiology research and practice2026
Short- and long-term risk stratification in acutely ill medical patients by implementing D-dimer in the emergency setting - A prospective cohort study.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: D-dimer testing is commonly used in emergency departments (EDs) to rule out thromboembolic events. However, elevated D-dimer levels may also be associated with an increased risk of mortality, independent of thromboembolism. Methods: This prospective observational study enrolled acutely ill medical ED patients. D-dimer measurements were conducted as part of biobanking at ED presentation. Survival at 30, 90, and 360 days was analyzed in relation to D-dimer, and Receiver operating characteristic (ROC) curves and logistic regressions were performed. Results: A total of 1035 patients were included (56% male; 61 years [IQR 46-74]). Median follow-up was 764 days (7.7% mortality). Elevated D-dimer (≥0.5 μg/mL) was observed in 46.4% of patients. Thirty-day mortality was 4.8% in patients with elevated D-dimer versus 0.2% with normal D-dimer levels (log-rank Conclusion: In unselected ED patients, D-dimer independently predicts 30- and 360-day mortality. Beyond its diagnostic role for VTE, an elevated D-dimer-particularly in patients with no VTE and discharge from the ED-identifies individuals at increased short- and long-term risk. Incorporating D-dimer (e.g., ≥ 0.75 μg/mL) into routine risk stratification may support targeted follow-up and post-discharge management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.